Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-26-260812
Filing Date
2026-06-08
Accepted
2026-06-08 09:17:41
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A rntx-defa14a-2026.htm DEFA14A 20008
2 GRAPHIC img142772922_0.jpg GRAPHIC 805349
3 GRAPHIC img142772922_1.jpg GRAPHIC 666516
  Complete submission text file 0001193125-26-260812.txt   2044192
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Rein Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38130 | Film No.: 261071198
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)